Onco360® Has Been Selected as a National Pharmacy Partner for PIMJETMI® (pimicotinib)

On November 18, 2026 Onco360, the nation’s leading independent Specialty Pharmacy, reported it has been selected by EMD Serono for PIMJETMI (pimicotinib), indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitations or severe morbidity.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"For patients whose condition makes surgery particularly challenging, access to additional treatment options is especially important. We’re proud to partner with EMD Serono and provide access to innovative treatment options that help ensure patients receive the specialized care, support, and compassion they deserve," said Benito Fernandez, Chief Commercial Officer.

PIMJETMI is a kinase inhibitor that inhibits colony-stimulating factor 1 receptor (CSF-1R). In vitro, PIMJETMI inhibited CSF-1R kinase activity and CSF-1R-dependent cell proliferation.1 The recommended PIMJETMI dosage is 50 mg orally once daily with or without food.

PIMJETMI efficacy was evaluated in the MANEUVER study (NCT05804045), a double-blind, randomized (2:1), placebo-controlled, international trial in patients with TGCT for whom surgical resection may cause dysfunction or serious complications.2 The major efficacy outcome measure was overall response rate (ORR) at Week 25. ORR was 56% (95% CI: 42, 68) in the PIMJETMI arm and 3.2% (95% CI: 0.1, 17) in the placebo arm. Median duration of response (DOR) was not reached in the PIMJETMI arm; 91% had a DOR ≥ 6 months, and 77% had a DOR ≥ 12 months. The most common (>20%) adverse reactions were pruritus, rash, facial edema, periorbital edema, fatigue, nausea, headache, and peripheral edema. The most common (>30%) lab abnormalities were increased creatine phosphokinase, increased lactate dehydrogenase, increased aspartate aminotransferase, increased lipase, increased cholesterol, amylase, and increased alanine aminotransferase.

(Press release, EMD Serono, NOV 18, 2026, View Source [SID1234674938])

Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model with Daily Dosing of Elraglusib Oral Tablet at ENA 2026

On November 18, 2026 Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers, reported new preclinical data demonstrating that daily oral administration of elraglusib achieved up to 77% tumor growth inhibition as monotherapy in an aggressive melanoma model, with greater antitumor activity associated with increased drug exposure. The findings, presented at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), also demonstrated changes in the tumor immune microenvironment consistent with enhanced antitumor immune activity, supporting the continued development of Elraglusib Oral Tablet in the upcoming Phase 1/2 clinical trial to be initiated in the first quarter of 2027.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These results reinforce our strategy to advance elraglusib as a daily oral therapy and expand its potential applications in oncology," said Daniel Schmitt, President and Chief Executive Officer of Actuate Therapeutics. "The exposure-response findings provide valuable insights to inform our upcoming clinical development program, while the observed effects on the tumor immune microenvironment further support the potential of elraglusib as both a monotherapy and in combination with other cancer treatments. We look forward to initiating our Phase 1/2 clinical trial in the first quarter of 2027, beginning with patients with refractory metastatic melanoma."

From intermittent IV dosing to continuous daily oral therapy

Elraglusib has been developed clinically as an intravenous (IV) infusion administered once or twice weekly, primarily in combination with chemotherapy. That approach includes the randomized Phase 2 trial in metastatic pancreatic cancer in which a once weekly IV infusion of elraglusib plus gemcitabine/nab-paclitaxel (GnP) versus GnP alone showed a statistically significant improvement in median overall survival, the primary endpoint in the study. Actuate is now advancing an oral tablet formulation designed for daily dosing. The goal is continuous drug exposure and sustained inhibition of glycogen synthase kinase-3β (GSK-3β), the target through which elraglusib acts on both tumor cells and immune cells.

The poster reports the first in vivo efficacy study of daily oral elraglusib. The study demonstrated significant single-agent antitumor activity with daily oral elraglusib in a preclinical melanoma model, with greater tumor growth inhibition observed at higher drug exposures.

"These findings provide important new insights into the relationship between elraglusib exposure and antitumor activity," said Andrey Ugolkov, MD, PhD, Senior Director, Clinical Science at Actuate Therapeutics and presenting author. "In this aggressive melanoma model, we observed greater tumor growth inhibition with increased drug exposure, alongside favorable changes in immune cell populations within the tumor microenvironment. Together, these findings support further investigation of daily oral dosing as a strategy to sustain GSK-3 inhibition and potentially enhance the antitumor activity of elraglusib."

Key Findings

Daily oral elraglusib demonstrated greater antitumor activity at higher drug exposures. In mice bearing B16F10 melanoma tumors, elraglusib spray-dried dispersion (SDD), the active component of the Elraglusib Oral Tablet formulation, achieved tumor growth inhibition (TGI) of 50% with once-daily dosing and 77% with twice-daily dosing. Both dosing regimens significantly reduced tumor weight compared with those achieved with the control vehicle (P<0.05).
Daily oral elraglusib demonstrated immunomodulatory effects in the tumor microenvironment. A 42-parameter spectral flow cytometry analysis of B16F10 tumors following seven days of treatment showed increased accumulation of cytotoxic CD8+ T cells and natural killer (NK) cells, alongside reductions in Ly6G+ neutrophil/polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-like populations. These findings suggest that daily oral elraglusib may promote a more favorable tumor immune microenvironment by increasing immune effector cell populations while reducing potentially immunosuppressive myeloid cells.
Preclinical findings inform the planned Phase 1/2 clinical trial. Preclinical exposure-response modeling suggests that drug exposures associated with significant antitumor activity in the B16F10 melanoma model may be achievable in humans with Elraglusib Oral Tablet administered once or twice daily. These projections will inform clinical development, while human pharmacokinetic and safety data from the Phase 1 portion of the planned study will guide dose selection and determination of the recommended Phase 2 dose (RP2D).
Poster Presentation Details

Title: Evaluation of antitumor activity of oral elraglusib in B16F10 melanoma model
Presenting Author: Andrey Ugolkov, MD, PhD, Actuate Therapeutics
Poster Number: PB-142, Exhibition Hall poster area
Session: Translational Studies
Date: November 18, 2026

The poster is available on the Publications page of Actuate’s website at www.actuatetherapeutics.com.

(Press release, Actuate Therapeutics, NOV 18, 2026, View Source [SID1234674907])

SELLAS Life Sciences Announces Pricing of $150.0 Million Underwritten Public Offering

On November 18, 2026 SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, reported the pricing of its previously announced underwritten public offering of 11,538,462 shares of its common stock at a public offering price of $13.00 per share. All of the shares in the offering will be sold by SELLAS, with gross proceeds to SELLAS expected to be $150.0 million before deducting underwriting discounts and commissions and offering expenses. In addition, SELLAS has also granted the underwriters a 30-day option to purchase up to 1,730,769 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on November 20, 2026, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

J.P. Morgan and TD Cowen are acting as the lead book-running managers for the offering. Mizuho is also acting as a book-running manager for the offering. A.G.P./Alliance Global Partners and Maxim Group LLC are acting as lead managers for the offering.

The public offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-294504) that was previously filed with the Securities and Exchange Commission (the "SEC") on March 20, 2026, and became automatically effective upon filing. The preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering has been filed with the SEC, and a final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at View Source The offering is being made only by means of a prospectus and related prospectus supplement, copies of which may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]; or TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected].

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

(Press release, Sellas Life Sciences, NOV 18, 2026, View Source [SID1234674923])

Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis

On November 18, 2026 Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, reported that it has aligned with the FDA on the design of its registrational Phase 3 trial of REC-4881, an investigational oral MEK1/2 inhibitor for the treatment of familial adenomatous polyposis (FAP). The alignment includes a composite event-free survival primary endpoint with a novel, clinically meaningful component: excision of an adenoma 10 mm or larger in either the upper or lower gastrointestinal (GI) tract. The trial is on track to begin in the second half of 2027.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy for FAP was identified through unbiased phenotypic screening using Recursion’s AI foundation models.

"Adenomas 10 millimeters and larger are associated with increased cancer risk and are nowadays routinely removed in patients with FAP. However, removal carries risks of bleeding and perforation, alongside the burden of repeated procedures and intensive surveillance," said Dr. Evelien Dekker, Head of Expert Clinic for Familial and Hereditary Polyposis and Colorectal Cancer, and Professor of Gastrointestinal Oncology, Amsterdam University Medical Center. "There is a substantial unmet need for a therapy that could prevent adenomas from reaching this size or developing in cancer. Reducing the need for these interventions could provide a meaningful benefit to patients."

"Patients with familial adenomatous polyposis face a lifelong burden of endoscopic surveillance, repeated interventions, and frequently major surgery. A medical therapy that could safely and durably prevent the progression of adenomas, reduce the need for endoscopic interventions, and potentially delay or avoid major surgery would represent a significant advance in the management of FAP," said Dr. Robert Hüneburg, MD, Senior Gastroenterologist and Head of the Hereditary Tumor Clinic, National Center for Hereditary Tumor Syndromes, Department of Internal Medicine I, University Hospital Bonn, Germany.

"For people living with FAP, colectomy does not end the disease. Patients continue to face decades of lifelong surveillance, repeated polyp removal and, for some, further major surgery," said Najat Khan, Ph.D., President and Chief Executive Officer of Recursion. "Our Phase 2 TUPELO results showed substantial and rapid reductions in polyp burden across the GI tract, including larger, higher-risk polyps, supporting our advancement toward a registrational trial. Securing FDA alignment on a novel component of our primary endpoint – counting the removal of adenomas 10 mm or larger across both the upper and lower GI tract as events – is a key milestone, reflecting an important and clinically meaningful intervention in FAP care. We appreciate the FDA’s constructive engagement and look forward to starting the trial in the second half of 2027, with the goal of bringing a much-needed treatment option to people living with FAP."

About the Phase 3 registrational trial

The registrational Phase 3 trial is a randomized, double-blind, placebo-controlled, event-driven study expected to enroll approximately 200 patients with FAP aged 18 and older who have had a colectomy or proctocolectomy. The trial will evaluate REC-4881 at a dose of 4 mg, with the dosing schedule that will be determined based on data emerging from the ongoing TUPELO trial. Patients in both arms will be monitored with comprehensive endoscopic surveillance.

The primary endpoint is event-free survival, measured from randomization to the first occurrence of any of the following events: excision of an adenoma ≥10 mm in either the upper or lower GI tract, meeting prespecified criteria for multiple types of FAP-related surgery, development of high-grade dysplasia or cancer, or death from any cause. Modified Spigelman stage progression and total polyp burden will be included among secondary endpoints. The trial design will include a prespecified interim analysis.

Adenoma size is one of the main measures clinicians use to assess risk in FAP. Adenomas 10 mm or larger are associated with an increased risk of high-grade dysplasia and cancer, and their removal may require advanced endoscopic techniques that carry risks of bleeding, intestinal perforation and incomplete resection requiring repeat intervention. Once an adenoma reaches this size, patients typically require more frequent surveillance, repeated endoscopic interventions, and additional complicated and life altering procedures. Adenomas of this size occur regularly over the course of the disease in both the upper and lower GI tract. By counting qualifying excisions in either region as events, the primary endpoint captures a common and consequential intervention across FAP care. These events are expected to contribute meaningfully to the trial’s event rate while reflecting decisions that directly shape clinical care.

About FAP

FAP is a rare, inherited disease that affects more than 50,000 patients in the US and EU5, with no approved pharmacologic therapies. It is caused by mutations in the APC gene, and without surgery to remove the colon, the lifetime risk of colorectal cancer approaches 100%. Colectomy does not stop the disease, as polyps continue to form in the remaining rectum or ileal pouch and in the upper GI tract, so patients face lifelong endoscopic surveillance, repeated polyp removal and, for some, further major surgery. Based on Company estimates, FAP represents a potential $15 billion opportunity.

Among the approximately 35,000 post-colectomy patients, upper GI disease is the area of greatest unmet need. Nearly all patients develop adenomas in the duodenum, and duodenal or ampullary cancer is a leading cause of cancer-related death after colectomy. The thin duodenal wall raises the risk of bleeding and perforation when these polyps are removed. When endoscopy can no longer control the disease, patients may need major surgery, such as removal of the duodenum or a Whipple procedure, which carries significant morbidity and a long recovery.

About REC-4881 and the TUPELO trial

REC-4881 is an investigational, oral, allosteric MEK1/2 inhibitor with FDA Orphan Drug and Fast Track designations for FAP. It is designed to address both the Wnt/β-catenin and MAPK pathways and was identified through unbiased phenotypic screening using Recursion’s AI foundation models. REC-4881 is currently being evaluated in the ongoing Phase 1b/2 TUPELO trial (NCT05552755) in post-colectomy patients aged 18 and older, and its registrational Phase 3 trial is expected to begin in the second half of 2027.

In updated TUPELO data presented at CGA-IGC on November 2, 2026, patients had a 47% median reduction in total polyp burden after 12 weeks of treatment with REC-4881 4 mg once daily, with approximately 1 in 3 achieving reductions of 65% or more. Activity was seen throughout the GI tract. Nearly 1 in 2 patients in the upper GI and more than 1 in 3 in the lower GI achieved polyp burden reductions of 65% or more, two patients achieved reductions of 98% or more in the upper GI, and half improved by at least one Spigelman stage. Twelve weeks after stopping treatment, 85% of evaluable patients remained below baseline. Six of eight patients with polyps larger than 5 mm at baseline had fewer of these polyps after 12 weeks, including two whose counts fell from more than 90 to one. No new safety signals were observed. The highest-grade treatment-related adverse event was Grade 1 or 2 in 81% of patients and Grade 3 in 15%, with no Grade 4 or 5 events.

(Press release, Recursion Pharmaceuticals, NOV 18, 2026, View Source [SID1234674939])

Avenzo Therapeutics Presents Positive Preliminary Results from the Phase 1 Study of AVZO-1418, a Potentially Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, at the 38th EORTC-NCI-AACR Symposium

On November 18, 2026 Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, reported positive preliminary clinical data from the Phase 1 portion of the Phase 1/2 AVENTINE-1 study evaluating AVZO-1418 in patients with locally advanced or metastatic solid tumors. The data highlight the pan-tumor potential of AVZO-1418 with objective responses observed across five of eight tumor types. Preliminary efficacy data also showed an objective response rate (ORR) of 63% in 19 evaluable patients with heavily pretreated epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), the majority of whom were in 3rd line or later. AVZO-1418 also demonstrated a favorable safety profile with a low incidence of Grade 3/4 hematologic adverse events. The data are being presented as a poster at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium in Barcelona, Spain, on November 18, 2026, from 12:00 p.m. to 7:00 p.m. CET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"AVZO-1418 has shown encouraging preliminary activity across multiple tumor types, pointing to its potential as a pan-tumor therapy," said Dr. Stephen Liu, Division Chief of Hematology/Oncology at MedStar Georgetown University Hospital, part of the MedStar Georgetown Cancer Institute. "I am especially encouraged by the strong efficacy signal and tolerability of AVZO-1418 in patients with EGFR-mutant NSCLC, the majority of whom received a prior 3rd generation EGFR TKI and platinum-based chemotherapy and have limited next options."

Clinical Data for AVENTINE-1, Phase 1/2 Study of AVZO-1418
As of the October 19, 2026 data cutoff, 61 patients with advanced solid tumors had received AVZO-1418 in the Phase 1 dose-escalation and backfill portion of the Phase 1/2 AVENTINE-1 study at doses of 2 to 6 mg/kg every two weeks (Q2W) or 6 mg/kg every three weeks (Q3W).

Patients included those with NSCLC-wild-type (NSCLC-WT) (n=20), EGFR-mutant NSCLC (EGFRm NSCLC) (n=19), colorectal cancer (CRC) (n=6), biliary tract cancer (BTC) (n=4), squamous cell carcinoma of the head and neck (SCCHN) (n=4), urothelial cancer (UC) (n=3), and other solid tumors (n=5). The backfill portion of the study was enriched for EGFRm NSCLC based on the strong early efficacy signal.

All patients (n=61) had received a median of two prior lines of systemic therapy in the advanced or metastatic setting (range 1 to 6), with 41% having received two prior lines of systemic therapy and 34% having received three or more prior lines. 84% of patients had received platinum-based chemotherapy and 54% had received anti-PD-(L)1 immunotherapy.

Patients with EGFRm NSCLC (n=19) had received a median of two prior lines of systemic therapy in the advanced or metastatic setting (range 1 to 4), with 47% having received two prior lines of systemic therapy and 16% having received three or more prior lines. 58% of patients had received platinum-based chemotherapy and all had received a prior 3rd generation EGFR tyrosine kinase inhibitor (TKI). At baseline, 63% of patients had an exon 19 deletion and 32% had an exon 21 L858R mutation.

Preliminary Safety Results
The overall safety population included 61 patients, with 48 patients treated at 2 to 5.5 mg/kg Q2W dose levels and 13 patients treated at 6 mg/kg Q2W and Q3W dose levels.

AVZO-1418 was generally well tolerated in the 2 to 5.5 mg/kg Q2W group (n=48)

No dose-limiting toxicities (DLTs) were observed.
Treatment-emergent adverse events (TEAEs) reported in >20% of patients were nausea, alopecia, fatigue, anemia, vomiting, stomatitis, headache, constipation, and decreased appetite. The majority of these events were Grade 1 or 2.
Anemia and neutrophil count decreased were reported as TEAEs in 33% and 19% of patients, with Grade 3/4 events reported in 4% and 6%, respectively.
Prophylactic granulocyte colony-stimulating factor (G-CSF) was not required in the study.
The 6 mg/kg dose level, dosed by actual body weight, exceeded the maximum tolerated dose (MTD) on both the Q2W and Q3W schedules, with two DLTs reported in each cohort.

Preliminary Efficacy Results
Preliminary efficacy data were available for 48 evaluable patients with measurable disease at baseline and at least one evaluable post-baseline scan. An additional seven patients remained on treatment and had not yet reached a post-baseline scan at the data cutoff date, and six patients were off treatment prior to an evaluable post-baseline scan for reasons other than disease progression.

Data are as of the cutoff date of October 19, 2026, with efficacy follow-up through November 5, 2026.

Responses were assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The ORRs reported below include confirmed partial responses and unconfirmed partial responses in patients who remain on treatment awaiting confirmatory scans.

Preliminary efficacy results across all tumor types suggest pan-tumor potential (n=48)

Responses were observed across six dose levels in five of eight tumor types (EGFRm NSCLC, UC, CRC, SCCHN, NSCLC-WT).
ORR was 38% (18 of 48 patients; 95% confidence interval (CI), 24.0%–52.6%), including 16 patients with confirmed partial responses (one patient with CRC confirmed their response after the efficacy follow up date), and two patients with unconfirmed partial responses who remained on treatment awaiting confirmatory scans.
26 of 48 patients remained on treatment as of the data cutoff date, including 17 of 18 responders.
13 patients had been on treatment for 24 weeks or longer.
Strong efficacy signal in patients with EGFRm NSCLC, majority of whom were previously treated with both a 3rd generation EGFR TKI and platinum-based chemotherapy (n=19)

ORR was 63% (12 of 19 patients; 95% CI, 38.4%–83.7%), including 10 patients with confirmed partial responses and two with unconfirmed partial responses who remained on treatment awaiting confirmatory scans, with multiple responses for 24 weeks or longer.
100% of patients achieved tumor reduction on their first post-baseline scan.
15 of 19 patients remained on treatment as of the data cutoff date, including:
11 responders.
Four patients with tumor reductions (three with >20% reduction from baseline) awaiting their next scans.
Responses were observed across five dose levels.
"We believe the preliminary data for AVZO-1418, with responses in five of eight tumor types, support its potential as a broadly active, pan-tumor therapy," said Mohammad Hirmand, M.D., Co-founder and Chief Medical Officer of Avenzo Therapeutics. "We’re particularly excited by the strong signal in EGFR-mutant NSCLC, where patients urgently need new treatment options. We are pursuing a rapid development plan that includes global expansion and further evaluation in multiple tumor types, with the goal of bringing this potentially transformative therapy to patients as quickly as possible."

About AVZO-1418
AVZO-1418 is a potentially best-in-class EGFR/HER3 bispecific antibody-drug conjugate (ADC) in development for locally advanced or metastatic solid tumors. It is designed with higher binding affinity for HER3 than EGFR to enhance delivery of its topoisomerase I inhibitor payload to EGFR/HER3-expressing tumors while limiting effects on healthy tissue. This dual-targeting approach may support activity across multiple tumor types, including EGFR-mutant non-small cell lung cancer. AVZO-1418 is being evaluated as monotherapy in the Phase 1 portion of the Phase 1/2 AVENTINE-1 study, with combination regimens also planned. Avenzo holds exclusive global rights, excluding Greater China, from DualityBio to develop, manufacture and commercialize AVZO-1418.

(Press release, Avenzo Therapeutics, NOV 18, 2026, View Source [SID1234674908])